Clinical trials: Hypofractionated Dose
Prostate Adenocarcinoma
ZOLEDRONIC ASSOCIATED With Hight Hypofractionated Radiotherapy Dose in Bone Metastases Vertebral Prostate Adenocarcinoma
This study will determine the delayed neurotoxicity (12 months) of a hypofractionated high dose irradiation (3 Gy x 9) associated with zoledronic acid.
- Trial name
- GEMO (NCT01219790)
- Testing
- external radiotherapy, Acide zoledronic
- Where
- 3 sites in France
- Volunteers
- 30 people
- Sponsor
- Institut Cancerologie de l'Ouest
Prostate Cancer
CyberKnife Ultra-hypofractionated SBRT for Localized PROStatE cancEr
This is a prospective observational study. The study will proceed with the enrollment of 60 patients in 2 years. he aim of the present study is to evaluate effectiveness of ultra-hypofractionated (UH) CyberKnife Stereotactic Body…
- Trial name
- PRO-SPEED (NCT06331013)
- Testing
- CyberKnife ultra-hypofractionated SBRT
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- European Institute of Oncology
Pancreatic Adenocarcinoma
Dose-Painted Intensity Modulated Radiotherapy Pancreas (DP-IMRT Pancreas)
This is a prospective non-randomised Phase I/II Radiotherapy (RT) study with patients recruited to escalated dose cohorts. Patients with resectable or borderline resectable (per the National Comprehensive Cancer Network (NCCN)…
- Trial name
- NCT06024824
- Testing
- Dose-Painted Intensity Modulated Radiotherapy
- Where
- 2 sites in Ireland
- Volunteers
- 49 people
- Sponsor
- Cancer Trials Ireland
Brain Cancer, MALIGNANT GLIOMA
Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma
The best dose of radiation to be given with bevacizumab is currently unknown. This study will use higher doses of radiation with bevacizumab than have been used before.
- Conditions
- Brain Cancer, MALIGNANT GLIOMA, Glioblastoma, Anaplastic Astrocytoma (AA)
- Trial name
- NCT01392209
- Testing
- Bevacizumab & Stereotactic Radiotherapy
- Where
- 5 sites in United States
- Volunteers
- 15 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Sarcoma, Fibrosarcoma
Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall
After a screening, which consists of biopsy, physical examination, initial diffusion-weighted magnetic resonance imaging (DWI-MRI), body computed tomography (CT) scan, blood tests and case analysis on Multidisciplinary Team (MDT)…
- Conditions
- Sarcoma, Fibrosarcoma, Leiomyosarcoma, Liposarcoma
- Trial name
- UN-RESARC (NCT03651375)
- Testing
- Sequential chemotherapy - 3 courses of AI, Hypofractionated radiotherapy
- Where
- Poland
- Volunteers
- 46 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
Carcinoma, Hepatocellular
Dose Escalation Study for Primary Hepatocellular Carcinoma
The purpose of this study is to determine the maximum tolerated dose of limited fractions of large dose radiation in an effort to achieve a biologically potent cancer therapy in selected patients with primary hepatocellular…
- Trial name
- SBF-HCC (NCT00243841)
- Testing
- Stereotactic Body Radiation
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Indiana University
Locally Advanced Cervical Carcinoma
HYpofractionated Pelvic Radiotherapy for Advanced Cervical Cancers INeligible for ChemoTherapy
BACKGROUND: For patients with locally advanced cervical cancer (LACC) ineligible for concurrent chemotherapy, radiotherapy (RT) alone achieves complete response rate (CRR) <70% and long-term locoregional control (LRC) <62%.
- Trial name
- HYACINCT (NCT05210270)
- Testing
- Hypofractionation
- Volunteers
- 55 people
- Sponsor
- University of Santo Tomas Hospital, Philippines